Ji Xing Pharmaceuticals reports positive data from Phase III PSVT treatment trial
Ji Xing Pharmaceuticals has announced positive topline data from its Phase III clinical trial of the etripamil nasal spray to …
Post
-
-
NeoImmuneTech presents data from Phase Ib trial of CAR-T therapy regimen
NeoImmuneTech has announced interim findings from its Phase Ib clinical trial of the combination of a CAR-T therapy with NT-I7 …
-
Five common misconceptions about mobile visits in clinical trials
With decentralization now widely recognized as an established tool in the clinical trial toolbox, an increasing number of sponsors and …
-
J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
The Rybrevant combination therapy by Johnson & Johnson (J&J) continues to be effective after three years in a study of …
-
Longboard reports interim data from Phase II extension trial of DEEs treatment
Longboard Pharmaceuticals has revealed interim results from its 52-week open-label extension of the Phase II PACIFIC Study of bexicaserin in …
-
Five common misconceptions about mobile visits in clinical trials
With decentralization now widely recognized as an established tool in the clinical trial toolbox, an increasing number of sponsors and …
-
J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
The Rybrevant combination therapy by Johnson & Johnson (J&J) continues to be effective after three years in a study of …
-
Longboard reports interim data from Phase II extension trial of DEEs treatment
Longboard Pharmaceuticals has revealed interim results from its 52-week open-label extension of the Phase II PACIFIC Study of bexicaserin in …
-
Cytonics concludes subject enrolment in Phase I knee osteoarthritis trial
Cytonics has announced the conclusion of subject enrolment in a Phase I clinical trial of CYT-108, for use as putative disease-modifying therapy …
-
Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial
A trial studying a higher dose of Biogen’s spinal muscular atrophy (SMA) drug Spinraza (nusinersen) has met the primary endpoint …
-
Plan for success and prepare for adversity – Clinical Trial Supply West Coast 2024
The 17th Annual Clinical Trial Supply West Coast 2024 conference in San Francisco will bring together regional industry leaders and …
-
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive …
-
Tempo doses first patient with tissue scaffolds in cancer surgery trial
Tempo Therapeutics has started the first in-human trial for its tissue regeneration product, TT101, in patients who have undergone surgical …
-
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial
Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in …
-
Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases
Aurinia Pharmaceuticals has dosed the first subject in a Phase Ia single ascending dose (SAD) clinical trial of AUR200, as …
